ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Boston, MA, USA:

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY)

This research study involves Niraparib as a possible treatment for triple negative breast cancer....

Active, not recruiting
Triple Negative Breast Cancer
Residual Disease
Radiation: Radiation Therapy
Drug: Niraparib

Phase 1

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 1 other location

This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer...

Active, not recruiting
Metastatic Breast Cancer
Triple Negative Breast Cancer
Biological: PVX-410
Drug: Pembrolizumab

Phase 1

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 2 other locations

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 11 other locations

with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.The names of the study d...

Enrolling
Breast Cancer
Breast Cancer Female
Drug: Carboplatin
Drug: Pembrolizumab

Phase 1, Phase 2

Filipa Lynce, MD

Boston, Massachusetts, United States

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Boston, Massachusetts, United States and 31 other locations

inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study...

Active, not recruiting
Breast Cancer
Biological: PVX-410
Biological: Durvalumab

Phase 1

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 4 other locations

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer...

Enrolling
Breast Cancer
Circulating Tumor DNA
Drug: Atezolizumab
Drug: Sacituzumab govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 6 other locations

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast ca...

Enrolling
HER2-negative Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan
Drug: Pembrolizumab

Phase 2

Mass General Brigham
Mass General Brigham

Boston, Massachusetts, United States and 4 other locations

oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoin ...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Boston, Massachusetts, United States and 23 other locations

This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative...

Active, not recruiting
Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
Breast Cancer
Drug: Paclitaxel
Drug: Onvansertib

Phase 1, Phase 2

Antonio Giordano, MD

Boston, Massachusetts, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems